Klin Farmakol Farm. 2008;22(3):105-109
Advances in the treatment of chronic viral hepatitis B and C
Chronic viral hepatitis B and C represent very well recognised financial and health problems in the developed countries. These viral infections and their consequences (liver cirrhosis and liver cancer) affect all social levels of population. Furthermore, health care in these cases may be very expensive. Applying of both preventive measures (as universal vaccination and screening for viral hepatitis) and specific antiviral treatment are the only two ways how to decrease the costs of care for patients with advanced liver disease. On the individual basis the antiviral treatment may prevent progression of liver lesion to liver cirrhosis and to hepatocellular carcinoma. In the recent years we are facing rapid improvement in the therapeutical options (new antiviral drugs) of chronic hepatitis B. In chronic hepatitis C there is a clear trend towards more individualised treatment regimens according to the baseline parameters in each case.
Keywords: Key words: viral heaptitic B, viral hepatitis C, interferon-alpha, lamivudin, adefovir, ribavirin.
Published: January 1, 2009 Show citation
References
- Husa P, Plíšek S, Šperl J, et al. Diagnostika a léčba chronické hepatitidy B. Doporučený postup ČHS a SIL ČLS JEP. Vnitř Lék 2005; 10: 1131-1137.
- Urbánek P, Husa P, Galský J, Šperl J, Kumpel P, Němeček V, Plíšek S, Volfová M. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Časopis lékařů českých 2008; 147 (5): příloha: I-XII.
- Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
Go to original source... 
Go to PubMed... - Manns MP, McHutchison JG, Gordon SC, et al. PEG-interferon alfa-2b in combination with ribavirin compared to interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001; 358: p 958-965. Go to original source... Go to PubMed...
- Zeuzem S, Pawlotsky J-M, Lukasiewicz E, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43: 250-257. Go to original source... Go to PubMed...
- Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43 (5): 954-960. Go to original source... Go to PubMed...
- Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964-970. Go to original source... Go to PubMed...
- Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, et al. Peginterferon-alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131 (2): 451-460. Go to original source... Go to PubMed...
- Benhamou Y, Pockros P, Rodriguez-Torres M, et al. The safety and efficacy of viramidine plus pegIFN alfa-2b versus ribavirin plus pegiFN alfa-2b in therapy-naive patients infected with HCV: phase 3 results (VISER1) Abstract 751, 41st Annual Meeting of European Association for the Study of the Liver, duben 2006. Go to original source...
- Reesink HW, Forestier N, Weegink CJ, et al. Initial results of a 14-day study of the hepatits C virus inhibitor VX-950, in combination with peginterferon-alfa-2a. Abstract 737, 41st Annual Meeting of European Association for the Study of the Liver, duben 2006. Go to original source...
- Dieterich D, Lawitz E, Nguyen T, et al. Early clearance of HCV RNA with valopicitabine (NM 283) plus peginterferon in treatment-naive patients with HCV-1 infection: first results from a phase IIb trial. Abstract 736, 41st Annual Meeting of European Association for the Study of the Liver, duben 2006. Go to original source...
- Pottage JC, et al. Short term antiviral acitivity and safety of ACH-806 (GS-9132), an NS4A antagonist, in HCV genotype 1 infected individuals. Abstract 783, 42nd Annual Meeting of European Association for the Study of the Liver, duben 2007. Go to original source...